Radiation Doses to the Heart Can Worsen Fatigue, Shortness of Breath in Cancer Patients

Radiation doses to the heart that occur during radiation therapy treatments for lung cancer, breast cancer, and lymphoma can increase fatigue, cause difficulty breathing and lower capacity for physical activity in patients with cancer, according to research presented at the American College of Cardiology’s Advancing the Cardiovascular Care of the Oncology Patient course. The course examines new science and best practices in assessing, diagnosing and treating the unique cardiovascular concerns of patients with cancer and/or those requiring survivorship care.

Cardiovascular disease is the second leading cause of death in cancer survivors, and it is estimated that 14.5 million cancer patients and survivors have significant cardiovascular risk factors. As more cancer patients are surviving and living longer, more long-term care issues are coming to light. Thoracic radiation therapy is a type of cancer treatment directed at the chest, heart and torso region and is highly effective in treating certain types of cancers in conjunction with chemotherapy. Thoracic radiation therapy can also cause side effects that can impact the quality of life.

Researchers in this study sought to examine thoracic radiation therapy as it impacted the quality of life in breast cancer, lung cancer and lymphoma patients. The study, conducted from 2015 to 2018, examined 130 patients with either breast cancer, lung cancer or mediastinal lymphoma who were treated with radiation to the chest. The median age of participants was 54 years and 78.5% were women.

Researchers collected data before radiation therapy was administered, immediately after the patient had received therapy, then five to nine months after the completion of radiation therapy. At each of these three-time points, patients were asked to self-report physical activity, which was assessed using the Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ). Fatigue and shortness of breath were assessed using the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue and Dyspnea Scales.

Different types of cancer showed different results:

  • Lung cancer and lymphoma participants reported an increase in fatigue and dyspnea immediately post-radiation therapy, which later improved. Each 1 Gy of increase in mean heart dose of radiation was associated with decreased GSLTPAQ scores. Additionally, every 10% increase in the volume of heart receiving a radiation dose of 5 Gy was associated with a significant reduction in GSLTPAQ scores.
  • Breast cancer participants reported significant increases in physical activity and decrease in fatigue over time. In this group, there was a non-significant trend toward increased fatigue with increasing radiation dose. However, when accounting for differences in radiation and chemotherapy treatment in these patients, high baseline moderate to vigorous GSLPTAQ scores were associated with improvements in fatigue over time.

“This study suggests that when a patient is treated with thoracic radiation therapy, it can have a negative impact on their quality of life early on. However, engaging in higher levels of physical activity before treatment may help to improve some of these symptoms over time,” said lead author Sheela Krishnan, MD, a fellow in the cardiovascular division of the Hospital of the University of Pennsylvania. “This study also confirms that increasing levels of physical activity during treatment are associated with concurrent improvements in quality of life. Though we cannot establish a clear causal relationship from these findings, it does emphasize that physical activity and quality of life are closely linked.”

Differences were observed between breast cancer and lung cancer and lymphoma patients, potentially due to differences in the delivered radiation doses. However, for all participants, accounting for the differences in chemotherapy and radiation dose they received, increases in physical activity over time were significantly associated with concurrent improvements in fatigue and shortness of breath. That’s why there are some who try the lymphoma new treatment.

“While our study is a small study, it suggests that high levels of physical activity prior to initiation of radiation therapy for cancer are associated with better physical functioning and quality of life with cancer treatment,” Krishnan said. “Additional work is still needed to understand the types and timing of exercises that can bring about the greatest benefit.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version